{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:11:50Z","timestamp":1790622710120,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["ECR\/2016\/000034"],"award-info":[{"award-number":["ECR\/2016\/000034"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["30-112\/2015 (BSR)"],"award-info":[{"award-number":["30-112\/2015 (BSR)"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["DBT\/2017\/BHU\/786"],"award-info":[{"award-number":["DBT\/2017\/BHU\/786"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.semcancer.2019.09.012","type":"journal-article","created":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T10:51:56Z","timestamp":1569063116000},"page":"8-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Drug repurposing for breast cancer therapy: Old weapon for new battle"],"prefix":"10.1016","volume":"68","author":[{"given":"Sadhna","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit Singh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash Chandra","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/tjbh.2015.2711","article-title":"Male breast cancer","volume":"12","author":"Yalaza","year":"2016","journal-title":"J. Breast Health"},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.012_bib0015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/1615-9861(200110)1:10<1216::AID-PROT1216>3.0.CO;2-P","article-title":"Proteomics of breast cancer for marker discovery and signal pathway profiling","volume":"1","author":"Hondermarck","year":"2001","journal-title":"PROTEOMICS: Int. Ed."},{"issue":"1\u20132","key":"10.1016\/j.semcancer.2019.09.012_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin. Med. Res."},{"issue":"Suppl. 4","key":"10.1016\/j.semcancer.2019.09.012_bib0025","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/bcr2734","article-title":"Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry","volume":"12","author":"Weigelt","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/513158","article-title":"Molecular markers for breast cancer: prediction on tumor behavior","volume":"2014","author":"Banin Hirata","year":"2014","journal-title":"Dis. Markers"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/BIC.S38394","article-title":"Novel molecular markers for breast cancer","volume":"8","author":"Inoue","year":"2016","journal-title":"Biomark. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.012_bib0045","first-page":"1339","article-title":"Treatment of breast cancer","volume":"81","author":"Maughan","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.semcancer.2019.09.012_bib0055","first-page":"17","article-title":"Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies","volume":"9","author":"Nounou","year":"2015","journal-title":"Breast Cancer: Basic Clin. Res."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5694\/j.1326-5377.2006.tb00208.x","article-title":"The prevention, detection, and management of breast cancer","volume":"184","author":"Houssami","year":"2006","journal-title":"Med. J. Aust."},{"issue":"9869","key":"10.1016\/j.semcancer.2019.09.012_bib0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/10731199.2010.494578","article-title":"Advances in novel drug delivery strategies for breast cancer therapy","volume":"38","author":"Dhankhar","year":"2010","journal-title":"Artif. Cells Blood Substitutes Immobilization Biotechnol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.012_bib0075","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jamasurg.2013.3393","article-title":"Breast cancer: a review for the general surgeon","volume":"148","author":"Matsen","year":"2013","journal-title":"JAMA Surg."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/bjc.2011.516","article-title":"Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer","volume":"106","author":"Tsang","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0085","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1634\/theoncologist.2014-0033","article-title":"Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA","volume":"19","author":"Swain","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1046\/j.1524-4741.2002.08204.x","article-title":"Toxicity of antiestrogens","volume":"8","author":"Hirsimaki","year":"2002","journal-title":"Breast J."},{"issue":"Suppl. 3","key":"10.1016\/j.semcancer.2019.09.012_bib0095","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0960-9776(09)70286-3","article-title":"Adjuvant endocrine therapy for premenopausal women with breast cancer","volume":"18","author":"Puhalla","year":"2009","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.012_bib0100","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-017-4624-7","article-title":"Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1\/2 mutation-associated breast cancer","volume":"168","author":"Telli","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-016-4010-x","article-title":"Use of complementary and alternative medicine and breast cancer survival in the Health, eating, activity, and lifestyle study","volume":"160","author":"Neuhouser","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/0019-509X.104486","article-title":"Breast cancer management: past, present and evolving","volume":"49","author":"Akram","year":"2012","journal-title":"Indian J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tips.2016.03.004","article-title":"Serendipity in cancer drug discovery: rational or coincidence?","volume":"37","author":"Prasad","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.012_bib0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.012_bib0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0150","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7147039","article-title":"A systematic framework for drug repositioning from integrated omics and drug phenotype profiles using pathway-drug network","volume":"2016","author":"Jadamba","year":"2016","journal-title":"Biomed Res. Int."},{"issue":"7607","key":"10.1016\/j.semcancer.2019.09.012_bib0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1067\/mcp.2001.115132","article-title":"New drug development in the United States from 1963 to 1999","volume":"69","author":"Dimasi","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3\u20134","key":"10.1016\/j.semcancer.2019.09.012_bib0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov. Today Therapeutic Strategies"},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.012_bib0170","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","volume":"60","author":"Heckman-Stoddard","year":"2017","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0175","first-page":"47","article-title":"Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction","volume":"8","author":"Boolell","year":"1996","journal-title":"Int. J. Impot. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/tera.1420160113","article-title":"Thalidomide embryopathy","volume":"16","author":"McBride","year":"1977","journal-title":"Teratology"},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.012_bib0185","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.semcancer.2019.09.012_bib0190","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.012_bib0195","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2009.25.4524","article-title":"Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Ning","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0200","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent advances in drug repositioning for the discovery of new anticancer drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Biol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.012_bib0205","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nchembio0807-447","article-title":"Systems chemical biology","volume":"3","author":"Oprea","year":"2007","journal-title":"Nat. Chem. Biol."},{"issue":"147","key":"10.1016\/j.semcancer.2019.09.012_bib0210","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0098-2017","article-title":"Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?","volume":"27","author":"Boyer","year":"2018","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.012_bib0215","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-2946-5-30","article-title":"Drug repositioning: a machine-learning approach through data integration","volume":"5","author":"Napolitano","year":"2013","journal-title":"J. Cheminform."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Brief. Bioinf."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0230","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/130620","article-title":"Network-based inference methods for drug repositioning","volume":"2015","author":"Chen","year":"2015","journal-title":"Comput. Math. Methods Med."},{"issue":"15","key":"10.1016\/j.semcancer.2019.09.012_bib0235","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2013.49.4799","article-title":"Precision oncology: an overview","volume":"31","author":"Garraway","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gpb.2015.01.006","article-title":"Biological databases for human research","volume":"13","author":"Zou","year":"2015","journal-title":"Genomics, Proteomics Bioinf."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgp261","article-title":"Cancer systems biology: a network modeling perspective","volume":"31","author":"Kreeger","year":"2010","journal-title":"Carcinogenesis"},{"issue":"5795","key":"10.1016\/j.semcancer.2019.09.012_bib0250","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc2044","article-title":"The Connectivity Map: a new tool for biomedical research","volume":"7","author":"Lamb","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0260","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/cmb.2008.10TT","article-title":"Identifying network of drug mode of action by gene expression profiling","volume":"16","author":"Iorio","year":"2009","journal-title":"J. Comput. Biol."},{"issue":"43","key":"10.1016\/j.semcancer.2019.09.012_bib0265","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0270","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0275","doi-asserted-by":"crossref","first-page":"D514","DOI":"10.1093\/nar\/gki033","article-title":"Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders","volume":"33","author":"Hamosh","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0280","first-page":"D991","article-title":"NCBI GEO: archive for functional genomics data sets--update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.semcancer.2019.09.012_bib0285","doi-asserted-by":"crossref","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0290","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein-protein interaction networks, integrated over the tree of life","volume":"43","author":"Szklarczyk","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0295","first-page":"D816","article-title":"The BioGRID interaction database: 2013 update","volume":"41","author":"Chatr-Aryamontri","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12864-017-3512-1","article-title":"HAPPI-2: a comprehensive and high-quality map of human annotated and predicted protein interactions","volume":"18","author":"Chen","year":"2017","journal-title":"BMC Genomics"},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0305","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0310","first-page":"D684","article-title":"STITCH: interaction networks of chemicals and proteins","volume":"36","author":"Kuhn","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0315","doi-asserted-by":"crossref","first-page":"D876","DOI":"10.1093\/nar\/gkr1011","article-title":"STITCH 3: zooming in on protein-chemical interactions","volume":"40","author":"Kuhn","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.012_bib0320","doi-asserted-by":"crossref","first-page":"D1128","DOI":"10.1093\/nar\/gkr797","article-title":"Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery","volume":"40","author":"Zhu","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0325","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijmedinf.2015.01.013","article-title":"Evaluation of usage patterns and user perception of the drug-drug interaction database SFINX","volume":"84","author":"Andersson","year":"2015","journal-title":"Int. J. Med. Inform."},{"issue":"D1","key":"10.1016\/j.semcancer.2019.09.012_bib0330","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0335","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3389\/fphar.2018.00583","article-title":"DeCoST: a new approach in drug repurposing from control system theory","volume":"9","author":"Nguyen","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0340","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tips.2009.11.006","article-title":"Unveiling the role of network and systems biology in drug discovery","volume":"31","author":"Pujol","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.012_bib0345","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0350","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/2326-6066.CIR-16-0048","article-title":"Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed","volume":"4","author":"Abu Eid","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0355","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1634\/theoncologist.2016-0268","article-title":"Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and Pertuzumab in patients with HER2-positive early stage breast cancer: a single center experience","volume":"22","author":"Singh","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12282-016-0666-7","article-title":"Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer","volume":"24","author":"Nakatsukasa","year":"2017","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0365","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1097-0142(195301)6:1<142::AID-CNCR2820060114>3.0.CO;2-W","article-title":"Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen\u203fmustard\u203flike activity","volume":"6","author":"Sykes","year":"1953","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0370","series-title":"Cancer Drug Discovery","author":"Kim","year":"2016"},{"issue":"5315","key":"10.1016\/j.semcancer.2019.09.012_bib0375","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/bmj.2.5315.1280","article-title":"Thiotepa in treatment of advanced breast cancer","volume":"2","author":"Lyons","year":"1962","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0380","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/1097-0142(197812)42:6<2534::AID-CNCR2820420605>3.0.CO;2-P","article-title":"Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy","volume":"42","author":"Perloff","year":"1978","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0385","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0390","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1568011013354723","article-title":"Anthracyclines: selected new developments, Current medicinal chemistry","volume":"1","author":"Binaschi","year":"2001","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0395","series-title":"Pharmacists, Doxorubicin Hydrochloride","author":"T.A.S.o.H.-S","year":"2016"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0400","series-title":"The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs","author":"Ravina","year":"2011"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0405","series-title":"Martindale: The Complete Drug Reference","author":"Brayfield","year":"2017"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0410","series-title":"Liposomal Doxorubicin (Caelyx, Myocet)","author":"M.C. Support","year":"2009"},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0415","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/09546630902789326","article-title":"Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders","volume":"20","author":"Moore","year":"2009","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0420","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.1962.03050300015003","article-title":"Five years clinical experience with 5-fluorouracil","volume":"181","author":"Ansfield","year":"1962","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.012_bib0425","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/1097-0142(19851115)56:10<2395::AID-CNCR2820561009>3.0.CO;2-H","article-title":"5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study","volume":"56","author":"Lokich","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0430","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1994.259","article-title":"Continuous 5-fluorouracil in the treatment of breast cancer","volume":"70","author":"Cameron","year":"1994","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2019.09.012_bib0435","first-page":"31","article-title":"Fluorouracil-based combinations in the treatment of metastatic breast cancer","volume":"12","author":"Klaassen","year":"1998","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0440","doi-asserted-by":"crossref","first-page":"R681","DOI":"10.1186\/bcr1274","article-title":"Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines","volume":"7","author":"Zoli","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0445","series-title":"Methotrexate","author":"Cronstein","year":"2000"},{"issue":"18","key":"10.1016\/j.semcancer.2019.09.012_bib0450","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate","volume":"309","author":"Jolivet","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.012_bib0455","first-page":"211","article-title":"An evaluation of folic acid antagonists in adults with neoplastic diseases: a study of 93 patients with incurable neoplasms","volume":"43","author":"Wright","year":"1951","journal-title":"J. Med. Assoc."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0460","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(197009)26:3<642::AID-CNCR2820260323>3.0.CO;2-4","article-title":"Systemic chemotherapy for advanced breast cancer","volume":"26","author":"Fracchia","year":"1970","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.012_bib0465","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM197602192940801","article-title":"Combination chemotherapy as an adjuvant treatment in operable breast cancer","volume":"294","author":"Bonadonna","year":"1976","journal-title":"N. Engl. J. Med."},{"issue":"7485","key":"10.1016\/j.semcancer.2019.09.012_bib0470","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 years\u2019 follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0475","series-title":"Excellence, Rheumatoid Arthritis. The Management of Rheumatoid Arthritis in Adults","author":"N.I.f.H.a.C","year":"2009"},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.012_bib0480","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.104.000554","article-title":"Identification of the cytosolic carboxylesterase catalyzing the 5\u2032-deoxy-5-fluorocytidine formation from capecitabine in human liver","volume":"32","author":"Tabata","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.012_bib0485","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0490","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1054\/bjoc.1999.0958","article-title":"A unified definition of clinical anthracycline resistance breast cancer","volume":"82","author":"Pivot","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0495","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ejca.2011.01.001","article-title":"A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I\/II study","volume":"47","author":"Villanueva","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0500","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.semcancer.2019.09.012_bib0505","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","article-title":"Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"28","author":"Sparano","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.012_bib0510","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/FPC.0000000000000086","article-title":"PharmGKB summary: gemcitabine pathway","volume":"24","author":"Alvarellos","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"issue":"Suppl. 5","key":"10.1016\/j.semcancer.2019.09.012_bib0515","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"issue":"Suppl. 6","key":"10.1016\/j.semcancer.2019.09.012_bib0520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00001813-199512006-00002","article-title":"Preclinical characteristics of gemcitabine","volume":"6","author":"Plunkett","year":"1995","journal-title":"Anticancer Drugs"},{"issue":"70","key":"10.1016\/j.semcancer.2019.09.012_bib0525","doi-asserted-by":"crossref","first-page":"115315","DOI":"10.18632\/oncotarget.23258","article-title":"Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0530","first-page":"353","article-title":"Gemcitabine. New first-line therapy for pancreatic cancer","volume":"4","author":"King","year":"1996","journal-title":"Cancer Pract."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0535","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002800050731","article-title":"Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study","volume":"41","author":"Takada","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.012_bib0540","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000058524","article-title":"Single-agent gemcitabine is active in previously treated metastatic breast cancer","volume":"60","author":"Spielmann","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0545","series-title":"Comprehensive Medicinal Chemistry II.: Computer-assisted Drug Design","author":"Mason","year":"2007"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0550","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2011.86","article-title":"Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer","volume":"104","author":"Stemmler","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"20","key":"10.1016\/j.semcancer.2019.09.012_bib0555","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0560","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0565","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10147-018-1359-3","article-title":"Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients","volume":"24","author":"Masuda","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.semcancer.2019.09.012_bib0570","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.012_bib0575","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2013.10.014","article-title":"Toremifene for breast cancer: a review of 20 years of data","volume":"14","author":"Vogel","year":"2014","journal-title":"Clin. Breast Cancer"},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.012_bib0585","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/17512433.2016.1231575","article-title":"Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women","volume":"9","author":"Provinciali","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.semcancer.2019.09.012_bib0590","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0595","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.3747\/co.25.3735","article-title":"Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects","volume":"25","author":"Pistelli","year":"2018","journal-title":"Curr. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2019.09.012_bib0600","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3816\/CBC.2005.s.008","article-title":"The history and mechanism of action of fulvestrant","volume":"6","author":"Carlson","year":"2005","journal-title":"Clin. Breast Cancer"},{"issue":"13","key":"10.1016\/j.semcancer.2019.09.012_bib0605","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1056\/NEJMoa1811714","article-title":"Overall survival with fulvestrant plus anastrozole in metastatic breast cancer","volume":"380","author":"Mehta","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0610","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of fulvestrant in breast cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol. Ther."},{"issue":"18","key":"10.1016\/j.semcancer.2019.09.012_bib0615","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2165\/00003495-200565180-00011","article-title":"Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women","volume":"65","author":"Cheer","year":"2005","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0620","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1871520614666141019191616","article-title":"Neoadjuvant strategies for triple negative breast cancer:\u2019 state-of-the-art\u2019 and future perspectives","volume":"15","author":"Carbognin","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.semcancer.2019.09.012_bib0625","first-page":"73","article-title":"Everolimus in the treatment of metastatic breast cancer","volume":"9","author":"Royce","year":"2015","journal-title":"Breast Cancer: Basic Clin. Res."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.012_bib0630","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"48","key":"10.1016\/j.semcancer.2019.09.012_bib0635","doi-asserted-by":"crossref","first-page":"19347","DOI":"10.1073\/pnas.1115945108","article-title":"In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid\u2013polymeric nanoparticles","volume":"108","author":"Chan","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0640","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","article-title":"Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials","volume":"1","author":"Sparano","year":"2000","journal-title":"Clin. Breast Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.012_bib0645","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14656566.6.7.1073","article-title":"The role of taxanes in the treatment of breast cancer","volume":"6","author":"Nabholtz","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"issue":"Suppl. 2","key":"10.1016\/j.semcancer.2019.09.012_bib0650","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience","volume":"9","author":"Crown","year":"2004","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0655","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1749-6632.1958.tb54906.x","article-title":"Role of chance observations in chemotherapy: vinca rosea","volume":"76","author":"Noble","year":"1958","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.012_bib0660","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/0277-5379(85)90241-X","article-title":"Mitomycin C and vinblastine in the treatment of advanced breast cancer","volume":"21","author":"Radford","year":"1985","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2019.09.012_bib0665","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000227243","article-title":"First-line and salvage therapy of metastatic breast cancer with mitomycin\/vinblastine","volume":"50","author":"Sedlacek","year":"1993","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.012_bib0670","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.bjc.6602367","article-title":"Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer","volume":"92","author":"Urruticoechea","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0675","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.1038\/s41598-018-35237-2","article-title":"Induction of N-Ras degradation by flunarizine-mediated autophagy","volume":"8","author":"Zheng","year":"2018","journal-title":"Sci. Rep."},{"issue":"7751","key":"10.1016\/j.semcancer.2019.09.012_bib0680","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1005-x","article-title":"Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism","volume":"568","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0685","first-page":"886","article-title":"ReDO_DB: the repurposing drugs in oncology database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"E Cancer Med. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.012_bib0690","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv235","article-title":"Nitric oxide inhibitors hit target for triple-negative breast cancer","volume":"107","author":"Firger","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.012_bib0695","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12282-019-00966-3","article-title":"PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation","volume":"26","author":"Gao","year":"2019","journal-title":"Breast Cancer"},{"issue":"7692","key":"10.1016\/j.semcancer.2019.09.012_bib0700","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature25465","article-title":"Asparagine bioavailability governs metastasis in a model of breast cancer","volume":"554","author":"Knott","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.012_bib0705","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.7150\/jca.24488","article-title":"Anticancer properties of fenofibrate: a repurposing use","volume":"9","author":"Lian","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2019.09.012_bib0710","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fphar.2018.00905","article-title":"Pathway-based drug repositioning for breast cancer molecular subtypes","volume":"9","author":"Mejia-Pedroza","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.012_bib0715","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1242\/dmm.030007","article-title":"Rethinking cancer: current challenges and opportunities in cancer research","volume":"10","author":"Cagan","year":"2017","journal-title":"Dis. Model. Mech."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.012_bib0720","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.mayocp.2015.08.017","article-title":"Characteristics of exceptional or super responders to cancer drugs","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"7466","key":"10.1016\/j.semcancer.2019.09.012_bib0725","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/501147a","article-title":"More cuts loom for US science","volume":"501","author":"Morello","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0730","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0149-2918(03)80085-1","article-title":"Thalidomide: a review of approved and investigational uses","volume":"25","author":"Matthews","year":"2003","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","article-title":"Renovation as innovation: is repurposing the future of drug discovery research?","volume":"24","author":"Neuberger","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"6330","key":"10.1016\/j.semcancer.2019.09.012_bib0740","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.012_bib0745","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.012_bib0750","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.012_bib0755","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer","volume":"1871","author":"Nowak-Sliwinska","year":"2019","journal-title":"Biochim. et Biophys. Acta. Rev. Cancer"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:25:12Z","timestamp":1777605912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X19302949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":151,"alternative-id":["S1044579X19302949"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.012","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing for breast cancer therapy: Old weapon for new battle","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}